Editas Medicine Inc (EDIT) Business News Sept. 02, 2025, 11:00 UTC Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate Full text
There are no comments here yet...